https://www.selleckchem.com/pr....oducts/sacituzumab-g
Two (6.1%) of 33 "at-risk" patients (patients with≥10 EDs plus patients who developed inhibitors) developed high-titer inhibitors and were withdrawn. No other safety concerns, including thromboembolic events, were identified. In the prophylaxis group (n=28), 67.9% were bleed free; all bleeds (n=15) were treated with one N9-GP injection; and overall, spontaneous, and traumatic ABRs were low (median ABRs of 0.0, 0.0, and 0.0, respectively; modeled mean ABRs of 0.31, 0.08, and 0.23, respectively). Estimated mean FIX trough ac